SCHEMBL6471994

SCHEMBL6471994

COc1ccc(-c2nc(-c3cc(C(=O)O)c(C)n3Cc3ccc(Cl)cc3)cs2)cc1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.51
NPC1 O15118 2/20 0.51
RAB9A P51151 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
ALDH1A1 P00352 2/20 0.51
EIF4E P06730 8/20 0.50
IDH1 O75874 1/20 0.47
KLKB1 P03952 1/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
THRB P10828 1/20 0.46
CNR2 P34972 1/20 0.45
CCR2 P41597 1/20 0.45
MAPT P10636 2/20 0.45
HPGD P15428 1/20 0.44
POLB P06746 1/20 0.44
ATM Q13315 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5045711 0.96 KDM4E (0.55) KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL6883231 0.94 KDM4E (0.50) KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL6879060 0.92 KDM4E (0.53) KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL6881059 0.92 EIF4E (0.50) KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL6884109 0.92 EIF4E (0.57) KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL6471925 0.90 KDM4E (0.53) KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL5044780 0.90 KDM4E (0.48) KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL6471628 0.90 KDM4E (0.50) KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL6882640 0.90 KDM4E (0.52) KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL6871859 0.89 EIF4E (0.49) KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1583762-A1 PYRROLYL-THIAZOLES AND THEIR USE AS CB 1 RECEPTOR INVERSE AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2005-10-12 EP claimed
WO-2004060888-A1 NOVEL CB 1 RECEPTOR INVERSE AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2004-07-22 WO claimed
US-20040147572-A1 Novel pyrrolyl-thiazole derivatives HOFFMAN-LA ROCHE INC. 2004-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147572-A1 Novel pyrrolyl-thiazole derivatives CNR1, CNR2, NPY1R KDM4E 2916/4885NPC1 500/4885RAB9A 1009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.